ArticleRevista da Associacao Medica Brasileira (1992)2025
Role of epiregulin levels in polycystic ovary syndrome patients: new findings and clinical significance.
Article in Revista da Associacao Medica Brasileira (1992), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePolycystic ovary syndrome, a prevalent endocrine disorder in reproductive-age women, is characterized by polycystic ovaries, oligoanovulation, and hyperandrogenemia. Epiregulin is a member of the epidermal growth factor (EGF) family, playing a crucial role in processes such as cell growth, differentiation, and proliferation. It is also known to be involved in reproductive system-specific mechanisms, including ovulation and oocyte maturation. This study aimed to investigate the role of epiregulin, an EGF family member implicated in ovulation and oocyte maturation, in women with polycystic ovary syndrome.
methodsSerum epiregulin levels were analyzed in 39 women with polycystic ovary syndrome and 28 healthy controls. Associations between epiregulin and clinical/metabolic parameters such as body mass index, insulin resistance, and androgen levels were assessed.
resultsWomen with polycystic ovary syndrome exhibited significantly lower epiregulin levels compared to controls (p<0.001). Epiregulin levels showed a negative correlation with polycystic ovary syndrome status and were inversely associated with body mass index, waist circumference, Homeostatic Model Assessment Insulin Resistance, triglycerides, fasting insulin, fasting glucose, and testosterone.
conclusionReduced epiregulin levels may contribute to the pathophysiology of polycystic ovary syndrome, highlighting its potential as a biomarker and therapeutic target. Further studies are needed to explore the underlying mechanisms and clinical implications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.